CONCEPT: Redifferentiation of thyroid carcinoma cells has the potential to increase the efficacy of radioactive iodine therapy in treatment-refractory, nonmedullary thyroid carcinoma (TC), leading to an improved disease outcome. Mammalian target of rapamycin (mTOR) is a key regulator of cell fate affecting survival and differentiation, with autophagy and inflammation as prominent downstream pathways. METHODS: The effects of mTOR inhibition were studied for its redifferentiation potential of the human TC cell lines BC-PAP, FTC133, and TPC1 by assessment of mRNA and protein expression of thyroid-specific genes and by performance of iodine uptake assays. RESULTS: In thyroid transcription factor 1 (TTF1)-expressing cell lines, mTOR inhibition promoted redifferentiation of TC cells by the up-regulation of human sodium-iodine symporter mRNA and protein expression. Furthermore, these cells exhibited markedly elevated iodine uptake capacity. Surprisingly, this redifferentiation process was not mediated by autophagy induced during mTOR inhibition or by inflammatory mediators but through transcriptional effects at the level of TTF1 expression. Accordingly, small interfering RNA inhibition of TTF1 completely abrogated the induction of human sodium-iodine symporter by mTOR inhibition. CONCLUSION: The present study has identified the TTF1-dependent molecular mechanisms through which the inhibition of mTOR leads to the redifferentiation of TC cells and subsequently to increased radioactive iodine uptake.
CONCEPT: Redifferentiation of thyroid carcinoma cells has the potential to increase the efficacy of radioactive iodine therapy in treatment-refractory, nonmedullary thyroid carcinoma (TC), leading to an improved disease outcome. Mammalian target of rapamycin (mTOR) is a key regulator of cell fate affecting survival and differentiation, with autophagy and inflammation as prominent downstream pathways. METHODS: The effects of mTOR inhibition were studied for its redifferentiation potential of the human TC cell lines BC-PAP, FTC133, and TPC1 by assessment of mRNA and protein expression of thyroid-specific genes and by performance of iodine uptake assays. RESULTS: In thyroid transcription factor 1 (TTF1)-expressing cell lines, mTOR inhibition promoted redifferentiation of TC cells by the up-regulation of humansodium-iodine symporter mRNA and protein expression. Furthermore, these cells exhibited markedly elevated iodine uptake capacity. Surprisingly, this redifferentiation process was not mediated by autophagy induced during mTOR inhibition or by inflammatory mediators but through transcriptional effects at the level of TTF1 expression. Accordingly, small interfering RNA inhibition of TTF1 completely abrogated the induction of humansodium-iodine symporter by mTOR inhibition. CONCLUSION: The present study has identified the TTF1-dependent molecular mechanisms through which the inhibition of mTOR leads to the redifferentiation of TC cells and subsequently to increased radioactive iodine uptake.
Authors: Angelique Huijbers; Theo S Plantinga; Leo A B Joosten; Katja K H Aben; Julius Gudmundsson; Martin den Heijer; Lambertus A L M Kiemeney; Mihai G Netea; Ad R M M Hermus; Romana T Netea-Maier Journal: Endocr Relat Cancer Date: 2012-05-03 Impact factor: 5.678
Authors: Elaine Cristina Lima de Souza; Alvaro Souto Padrón; William Miranda Oliveira Braga; Bruno Moulin de Andrade; Mário Vaisman; Luiz Eurico Nasciutti; Andrea Claudia Freitas Ferreira; Denise Pires de Carvalho Journal: J Endocrinol Date: 2010-04-14 Impact factor: 4.286
Authors: Alexandra Faustino; Joana P Couto; Helena Pópulo; Ana Sofia Rocha; Fernando Pardal; José Manuel Cameselle-Teijeiro; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares Journal: J Clin Endocrinol Metab Date: 2012-05-01 Impact factor: 5.958
Authors: Ana M Molina; Darren R Feldman; Martin H Voss; Michelle S Ginsberg; Michael S Baum; Dion R Brocks; Patricia M Fischer; Michael J Trinos; Sujata Patil; Robert J Motzer Journal: Cancer Date: 2011-09-06 Impact factor: 6.860
Authors: Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen Journal: J Clin Endocrinol Metab Date: 2008-08-19 Impact factor: 5.958
Authors: C A Fernández; M Puig-Domingo; F Lomeña; M Estorch; V Camacho Martí; A L Bittini; M Marazuela; J Santamaría; J Castro; P Martínez de Icaya; I Moraga; T Martín; A Megía; M Porta; D Mauricio; I Halperin Journal: J Endocrinol Invest Date: 2009-03 Impact factor: 4.256
Authors: Romana T Netea-Maier; Viola Klück; Theo S Plantinga; Johannes W A Smit Journal: Front Endocrinol (Lausanne) Date: 2015-02-18 Impact factor: 5.555
Authors: Theo S Plantinga; Marika H Tesselaar; Hans Morreau; Eleonora P M Corssmit; Brigith K Willemsen; Benno Kusters; A C H van Engen-van Grunsven; Johannes W A Smit; Romana T Netea-Maier Journal: Autophagy Date: 2016-04-22 Impact factor: 16.016
Authors: Ana Lopez-Campistrous; Esther Ekpe Adewuyi; Matthew G K Benesch; Yi Man Ko; Raymond Lai; Aducio Thiesen; Jay Dewald; Peng Wang; Karen Chu; Sunita Ghosh; David C Williams; Larissa J Vos; David N Brindley; Todd P W McMullen Journal: EBioMedicine Date: 2016-09-10 Impact factor: 8.143